Daré Bioscience closes Regulation A unit offering
Daré Bioscience, Inc. completed a closing of its previously announced Regulation A offering of Investor Units.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Form Type
8-K
Rhea-AI Filing Summary
Daré Bioscience, Inc. completed a closing of its previously announced Regulation A offering of Investor Units. In this closing, the company issued 3,470 Investor Units, each priced at $5.00 and consisting of one share of Series A Convertible Preferred Stock and two Investor Warrants.
The 3,470 Investor Units therefore represent 3,470 shares of Series A Preferred Stock and Investor Warrants to purchase up to 6,940 shares of Daré’s common stock. The offering is being conducted under an offering statement on Form 1-A qualified by the SEC, together with an offering circular and an offering circular supplement.
8-K Event Classification
Item 3.02 — Unregistered Sales of Equity Securities
1 item
Item 3.02
Unregistered Sales of Equity Securities
Securities
The company sold equity securities in a private placement or other unregistered transaction.
Key Figures
Maximum Investor Units Offered: 4,854,000 units
Investor Unit Price: $5.00 per unit
Investor Units Issued in Closing: 3,470 units
+3 more
6 metrics
Maximum Investor Units Offered
4,854,000 units
Regulation A Investor Unit offering size
Investor Unit Price
$5.00 per unit
Offering price for each Investor Unit
Investor Units Issued in Closing
3,470 units
Units issued in the reported closing
Series A Preferred Shares Issued
3,470 shares
One Series A Convertible Preferred share per unit
Investor Warrants Issued
6,940 warrants
Two Investor Warrants per unit to buy common stock
Common Shares Underlying Warrants
6,940 shares
Maximum common shares purchasable via Investor Warrants
Key Terms
Regulation A offering, Series A Convertible Preferred Stock, warrants, offering statement on Form 1-A, +1 more
5 terms
Regulation A offering regulatory
"completed a closing of our previously announced Regulation A offering of up to 4,854,000 units"
A Regulation A offering is a way for smaller companies to sell shares to the public without going through a full, traditional stock market listing. Think of it as a scaled-down public sale that gives everyday investors earlier access to private companies while generally requiring less paperwork and oversight than a full IPO—so it can offer growth opportunities but also carries higher risk and potentially less disclosure than fully regulated public stocks.
Series A Convertible Preferred Stock financial
"each consisting of one share of Series A Convertible Preferred Stock (the “Series A Preferred Stock”)"
Series A convertible preferred stock is a class of shares sold in an early funding round that gives investors a mix of protection and upside: it pays a priority claim over common shares if the company is sold or closes, but can be converted into ordinary shares to share in future growth. Think of it like a hybrid between a safer stake and a ticket to ownership; it matters to investors because it affects who controls the company, how future gains are split, and how much their investment is protected from downside.
warrants financial
"and two warrants, each to purchase one share of our common stock"
Warrants are special documents that give you the right to buy a company's stock at a set price before a certain date. They are often used as a way for companies to attract investors or raise money, and their value can increase if the company's stock price goes up.
offering statement on Form 1-A regulatory
"pursuant to our offering statement on Form 1-A (File No. 024-12688), as amended"
offering circular supplement regulatory
"the offering circular dated January 6, 2026, and the offering circular supplement dated March 26, 2026"
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
What did Daré Bioscience (DARE) announce in this 8-K filing?
Daré Bioscience reported completing a closing of its Regulation A offering of Investor Units. In this closing, it issued 3,470 Investor Units, each at $5.00, made up of Series A Convertible Preferred Stock and Investor Warrants to buy common shares.
How many Daré Bioscience (DARE) Investor Units were issued in this closing?
Daré Bioscience issued 3,470 Investor Units in this closing. Each unit includes one share of Series A Convertible Preferred Stock and two Investor Warrants, giving holders the right to purchase up to 6,940 shares of the company’s common stock in total.
What securities are included in each Daré Bioscience (DARE) Investor Unit?
Each Investor Unit consists of one share of Series A Convertible Preferred Stock and two Investor Warrants. Each Investor Warrant allows the purchase of one share of common stock, so each unit provides potential rights to acquire two shares of Daré’s common stock.
What is the offering price of Daré Bioscience (DARE) Investor Units?
Daré Bioscience’s Investor Units are offered at an offering price of $5.00 per unit. At this price, each unit bundles one share of Series A Convertible Preferred Stock with two Investor Warrants that can be exercised for additional common shares.
What is the maximum size of Daré Bioscience’s Regulation A Investor Unit offering?
Daré Bioscience’s Regulation A offering covers up to 4,854,000 Investor Units. The reported closing relates to 3,470 of these units; the broader offering framework is described in the company’s qualified Form 1-A, offering circular, and offering circular supplement.
Under what regulatory framework is Daré Bioscience (DARE) conducting this offering?
Daré Bioscience is conducting the Investor Unit offering under Regulation A, using an offering statement on Form 1-A. This statement, along with an offering circular and offering circular supplement qualified by the SEC, governs the terms and disclosure for participating investors.
AI-generated analysis. How Rhea-AI works. Not financial advice.
Accepted by SEC EDGAR
Learn about SEC filing dates